Display Settings:

Format

Send to:

Choose Destination

    J Am Osteopath Assoc. 2008 Jun;108(6):289-95.

    Improving clinical decisions for women at risk of osteoporosis: dual-femur bone mineral density testing.

    Cole RE.

    CCD, Director, Osteoporosis Testing Center of Michigan, 107 Chicago St, Brooklyn, MI 49230-9703, USA. RECFCC@aol.com

    CONTEXT: In bone mineral density (BMD) testing, unilateral hip analysis and lumbar spine measurement have been the clinical standard for diagnosis and treatment classification for postmenopausal women at risk of osteoporosis. OBJECTIVE: To determine if analysis of the bilateral hip in BMD testing has a clinical effect on diagnosis of osteoporosis and treatment classification of patients. METHODS: Dual-femur BMD test results from 313 postmenopausal women (mean age 61.2 years, range 32-90 years) were evaluated using standard BMD reference values for diagnosis and treatment classification. The author compared T scores for right and left femurs at three sites: femoral neck, trochanter, and total femur. Results: When the bilateral hip was considered in BMD testing and compared with unilateral hip results, a clinical change in diagnosis from normal to osteopenia occurred in 5.7% of subjects. In addition, a clinical change in diagnosis from osteopenia to osteoporosis occurred in 3.3% of subjects. A clinical change in treatment classification from "no treatment required" to "treatment required if one or more risk factors are present" occurred in 3% of subjects. A change in treatment classification from "treatment required if one or more risk factors are present" to "treatment required independent of risk factors" happened in 2.4% of subjects. CONCLUSION: When compared with BMD testing of the unilateral hip, inclusion of the bilateral hip in BMD testing resulted in a change in classification to a more severe diagnosis in a total of 9% of subjects, and to a more aggressive treatment category in a total of 5.4% of subjects. Dual-femur BMD testing may improve diagnosis and treatment classification for postmenopausal women at risk of osteoporosis.

    PMID: 18587077 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read